Literature DB >> 15677443

The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation.

Erwin Gäbele1, Shimon Reif, Shigeki Tsukada, Ramon Bataller, Yutaka Yata, Terry Morris, Laura W Schrum, David A Brenner, Richard A Rippe.   

Abstract

During fibrosis the hepatic stellate cell (HSC) undergoes a complex activation process characterized by increased proliferation and extracellular matrix deposition. The 70-kDa ribosomal S6 kinase (p70S6K) is activated by mitogens, growth factors, and hormones in a phosphatidylinositol 3-kinase-dependent manner. p70S6K regulates protein synthesis, proliferation, and cell cycle control. Because these processes are involved in HSC activation, we investigated the role of p70S6K in HSC proliferation, cell cycle control, and type I collagen expression. Platelet-derived growth factor (PDGF) stimulated p70S6K phosphorylation, which was blocked by LY294002, an inhibitor of phosphatidylinositol 3-kinase. Rapamycin blocked phosphorylation of p70S6K but had no affect on PDGF-induced Akt phosphorylation, positioning p70S6K downstream of Akt. Transforming growth factor-beta, which inhibits HSC proliferation, did not affect PDGF-induced p70S6K phosphorylation. Rapamycin treatment did not affect alpha1(I) collagen mRNA but reduced type I collagen protein secretion. Expression of smooth muscle alpha-actin was not affected by rapamycin treatment, indicating that HSC activation was not altered. Rapamycin inhibited serum-induced DNA synthesis approximately 2-fold. Moreover, rapamycin decreased expression of cyclins D1, D3, and E but not cyclin D2, Rb-Ser780, and Rb-Ser795. Together, p70S6K plays a crucial role in HSC proliferation, collagen expression, and cell cycle control, thus representing a potential therapeutic target for liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677443     DOI: 10.1074/jbc.M409444200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Withagulatin A inhibits hepatic stellate cell viability and procollagen I production through Akt and Smad signaling pathways.

Authors:  Qiong Liu; Jing Chen; Xu Wang; Liang Yu; Li-hong Hu; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

2.  Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.

Authors:  Cindy X Cai; Hema Buddha; Shobha Castelino-Prabhu; Zhiwei Zhang; Robert S Britton; Bruce R Bacon; Brent A Neuschwander-Tetri
Journal:  Dig Dis Sci       Date:  2017-02-13       Impact factor: 3.199

3.  Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway.

Authors:  Jianjian Zheng; Cunzao Wu; Ziqiang Xu; Peng Xia; Peihong Dong; Bicheng Chen; Fujun Yu
Journal:  Mol Cell Biochem       Date:  2014-08-23       Impact factor: 3.396

4.  Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258.

Authors:  Yuqing Liu; Xiao Ming Wen; Eric Lik Hang Lui; Scott L Friedman; Wei Cui; Nancy Pei Shan Ho; Lei Li; Tao Ye; Sheung Tat Fan; Hui Zhang
Journal:  Lab Invest       Date:  2009-08-10       Impact factor: 5.662

5.  Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production.

Authors:  Qiong Liu; Xu Wang; Yu Zhang; Chen-jing Li; Li-hong Hu; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2010-06-21       Impact factor: 6.150

6.  Septin4_i1 regulates apoptosis in hepatic stellate cells through peroxisome proliferator-activated receptor-γ/Akt/B-cell lymphoma 2 pathway.

Authors:  Dandan Zhu; Jianxin Wang; Xiaolei Sun; Jinling Chen; Yinong Duan; Jing Pan; Tianhua Xu; Yongwei Qin; Xingxin He; Caiqun Huang
Journal:  J Histochem Cytochem       Date:  2014-12-19       Impact factor: 2.479

7.  TNFalpha is required for cholestasis-induced liver fibrosis in the mouse.

Authors:  Erwin Gäbele; Matthias Froh; Gavin E Arteel; Takehiko Uesugi; Claus Hellerbrand; Jürgen Schölmerich; David A Brenner; Ronald G Thurman; Richard A Rippe
Journal:  Biochem Biophys Res Commun       Date:  2008-11-06       Impact factor: 3.575

Review 8.  Validation of anti-aging drugs by treating age-related diseases.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-03-28       Impact factor: 5.682

9.  Inhibitory effects of rapamycin on the different stages of hepatic fibrosis.

Authors:  Yun Jeung Kim; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee; Seung Moo Noh; Dae Young Kang; Byung Seok Lee
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

Authors:  Ainhoa Fernández-Yunquera; Cristina Ripoll; Rafael Bañares; Marta Puerto; Diego Rincón; Ismael Yepes; Vega Catalina; Magdalena Salcedo
Journal:  World J Transplant       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.